Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

Rhea-AI Summary

BioArctic (Nasdaq Stockholm: BIOA B)/b) reports that partner recorded preliminary global Leqembi sales of JPY 29.3 billion in the second quarter 2026. This generated a royalty to BioArctic of SEK 179 million, about 10% higher than the royalty for Q2 2025.

According to BioArctic, Q2 2025 royalty included a one-time Chinese stockpiling effect of around JPY 5.3 billion; excluding this, Q2 2026 royalty grew about 43% year-on-year. BioArctic’s full Q2 2026 report is scheduled for August 26, 2026. Leqembi is approved in 53 countries, with IV maintenance dosing approved in 8 countries and subcutaneous formulations progressing through regulatory processes in the US, Japan and China.

Positive

• Leqembi Q2 2026 sales JPY 29.3 billion globally, per Eisai
• Royalty to BioArctic SEK 179 million in Q2 2026, up ~10% vs Q2 2025
• Underlying royalty growth about 43% YoY excluding prior Chinese stockpiling effect
• Leqembi approvals in 53 countries, with IV maintenance dosing approved in 8 countries
• Subcutaneous Leqembi approved in the US and under review in Japan and China

Negative

• None.

News Explained

The preliminary sales disclosure also clarifies the arrangement: Eisai handles Leqembi’s global development, regulatory applications and commercialization, while BioArctic has no Alzheimer’s development costs and receives royalties on global sales.

News Market Reaction – B

-0.90%

2 alerts

-0.90% Session close to close

$63.50B Market Cap

1.2x Rel. Volume

In the Jul 29 session, B declined 0.90%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The supplied peer snapshot showed WPM at -0.54% and FNV at -0.60%, adding a broader market compariso...

Analysis

The supplied peer snapshot showed WPM at -0.54% and FNV at -0.60%, adding a broader market comparison to this royalty update. Low short positioning was an additional risk context; investors could watch the August report for confirmation.

Key Figures

Leqembi sales: JPY 29.3 billion BioArctic royalty: SEK 179 million Royalty growth: 10 percent +5 more

8 metrics

Leqembi sales JPY 29.3 billion Q2 2026 global sales

BioArctic royalty SEK 179 million Q2 2026

Royalty growth 10 percent Compared with Q2 2025

China stockpiling effect JPY 5.3 billion Included in Q2 2025 results

Adjusted royalty revenue growth 43 percent Q2 2026 versus Q2 2025, excluding stockpiling effect

Leqembi approvals 53 countries Current approval status stated in the article

Regulatory reviews 6 countries Current review status stated in the article

Q2 report date August 26, 2026 at 08:00 CEST BioArctic second-quarter report publication

Key Terms

monoclonal antibody, subcutaneous dosing, biologics license application, priority review, +1 more

5 terms

monoclonal antibody medical

"It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

subcutaneous dosing medical

"maintenance dosing with treatment every four weeks is approved"

Subcutaneous dosing is giving a drug by injection into the fatty layer just beneath the skin instead of into a vein or muscle. For investors, this matters because this route often makes medicines easier to use at home, can reduce administration costs, improve patient adherence, and influence device and manufacturing needs, all of which affect a product’s market appeal and revenue potential.

biologics license application regulatory

"the Biologics License Application for subcutaneous formulation"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

priority review regulatory

"the application was designated for priority review"

Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.

phase 3 clinical study medical

"Eisai's Phase 3 clinical study (AHEAD 3-45)"

A phase 3 clinical study is a late-stage, large-scale test of a medical treatment in many patients to confirm how well it works and to monitor side effects before regulators consider approval. Think of it as a final dress rehearsal where the treatment is tested in diverse, real-world conditions to prove benefits outweigh risks. Investors watch these results because positive outcomes can clear the path to regulatory approval, sales, and major value changes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 29.3 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 179 million, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025.

The results in Q2 2025 included a one-time stockpiling effect in the Chinese market of around JPY 5.3 billion. Excluding the stockpiling effect, royalty revenues in Q2 2026 grew approximately 43 percent compared to the same quarter last year.

BioArctic's report for the second quarter of 2026 will be published on August 26, 2026, at 08:00 CEST.

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on July 29, 2026, at 12.00 pm CEST.

For further information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180

Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08

About Leqembi® (lecanemab)

Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 8 countries, including the United Kingdom, China, the US and Japan, and applications have been filed in 12 countries and regions. In the US, Leqembi Iqlik® is approved for subcutaneous dosing with an autoinjector as a starting dose and maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. In January 2026, the Biologics License Application for subcutaneous formulation of Leqembi was accepted in China and in February, the application was designated for priority review.

Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

About the collaboration between BioArctic and Eisai

Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/sales-of-leqembi--totaled-29-3-billion-yen-in-the-second-quarter-2026,c4378245

The following files are available for download:

https://mb.cision.com/Main/9978/4378245/4205037.pdf

Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

 

View original content:https://www.prnewswire.com/news-releases/sales-of-leqembi-totaled-29-3-billion-yen-in-the-second-quarter-2026--302837662.html

SOURCE BioArctic

FAQ

How much were Leqembi sales in Q2 2026 for BioArctic’s partners Eisai and Biogen (BIOA B)?

Leqembi global sales were JPY 29.3 billion in Q2 2026. According to BioArctic, this figure reflects preliminary worldwide revenue reported by partner Eisai in connection with Biogen’s second-quarter 2026 report and forms the basis for BioArctic’s royalty income.

What royalty did BioArctic (BIOA B) receive from Leqembi sales in Q2 2026?

BioArctic recorded a SEK 179 million royalty from Leqembi in Q2 2026. According to BioArctic, this represents about a 10% increase versus the royalty booked in Q2 2025 and reflects its contractual share of global lecanemab sales.

How fast did BioArctic’s Leqembi royalty grow year-on-year in Q2 2026 (BIOA B)?

BioArctic’s Leqembi royalty grew about 10% year-on-year in Q2 2026. According to BioArctic, excluding a one-time Chinese stockpiling effect in Q2 2025, underlying royalty growth was approximately 43% compared with the same quarter of the previous year.

How did the Chinese stockpiling effect in 2025 impact BioArctic’s Leqembi royalties (BIOA)?

In Q2 2025, Leqembi revenue included a JPY 5.3 billion stockpiling effect in China. According to BioArctic, this one-time factor inflated the prior-year base; excluding it, Q2 2026 royalty revenue grew about 43% compared with Q2 2025 levels.

When will BioArctic publish its full Q2 2026 earnings report (BIOA B)?

BioArctic plans to publish its full Q2 2026 report on August 26, 2026 at 08:00 CEST. According to BioArctic, this report will provide detailed financial results beyond the preliminary Leqembi royalty disclosure released on July 29, 2026.

In how many countries is Leqembi approved as of Q2 2026 and what formulations exist?

Leqembi is approved in 53 countries worldwide as of Q2 2026. According to BioArctic, IV maintenance dosing every four weeks is approved in 8 countries, and a subcutaneous autoinjector formulation is approved in the US and under review in Japan and China.

What is the nature of BioArctic’s collaboration with Eisai on Leqembi (BIOA)?

BioArctic and Eisai have collaborated on lecanemab since 2005 under long-term development and commercialization agreements. According to BioArctic, Eisai leads global development and commercialization, while BioArctic bears no Alzheimer’s development costs and receives sales milestones plus royalties on worldwide Leqembi sales.